アブストラクト
| Title | 利尿薬, トルバプタン |
|---|---|
| Subtitle | 特集 Fantastic Four時代の心不全の治療戦略 位置づけ, 使いどころを再整理しよう |
| Authors | 堀内優 |
| Authors (kana) | |
| Organization | 三井記念病院循環器内科 |
| Journal | 月刊薬事 |
| Volume | 65 |
| Number | 9 |
| Page | 1755-1759 |
| Year/Month | 2023 / 7 |
| Article | 報告 |
| Publisher | じほう |
| Abstract | [Key Points] ●うっ血は心不全における主要な症状であり, 利尿薬治療により改善を図る必要がある. ●利尿薬治療の基本はループ利尿薬であるが, 近年多くの利尿薬が併用療法として検討されてきた. ●トルバプタンは集合管のバソプレシン2受容体に拮抗して水利尿効果を有する利尿薬である. ●トルバプタンは, 尿量を増加させ, 血清クレアチニン値の上昇を軽度に留めるが, 長期予後改善効果に関しては明らかでない. |
| Practice | 薬学 |
| Keywords |
- 全文ダウンロード： 従量制、基本料金制の方共に803円(税込) です。
参考文献
- 1) Zile MR, et al: Transition from chronic compensated to acute decompensated heart failure: pathophysiological insights obtained from continuous monitoring of intracardiac pressures. Circulation, 118:1433-1441, 2008
- 2) Ellison DH, et al: Diuretic Treatment in Heart Failure. N Engl J Med, 377:1964-1975, 2017
- 3) Jentzer JC, et al: Combination of loop diuretics with thiazide-type diuretics in heart failure. J Am Coll Cardiol, 56:1527-1534, 2010
- 4) Imamura T, et al: Urine osmolality estimated using urine urea nitrogen, sodium and creatinine can effectively predict response to tolvaptan in decompensated heart failure patients. Circ J, 77:1208-1213, 2013
- 5) Butler J, et al; National Heart Lung and Blood Institute Heart Failure Clinical Research Network: Efficacy and Safety of Spironolactone in Acute Heart Failure: The ATHENA-HF Randomized Clinical Trial. JAMA Cardiol, 2:950-958, 2017
残りの8件を表示する
- 6) Konstam MA, et al; Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators: Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA, 297:1319-1331, 2007
- 7) Cox ZL, et al: Diuretic Strategies for Loop Diuretic Resistance in Acute Heart Failure: The 3T Trial. JACC Heart Fail, 8:157-168, 2020
- 8) Imamura T, et al: Increased urine aquaporin-2 relative to plasma arginine vasopressin is a novel marker of response to tolvaptan in patients with decompensated heart failure. Circ J, 78:2240-2249, 2014
- 9) Mullens W, et al; ADVOR Study Group: Acetazolamide in Acute Decompensated Heart Failure with Volume Overload. N Engl J Med, 387:1185-1195, 2022
- 10) Voors AA, et al: The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial. Nat Med, 28:568-574, 2022
- 11) Solomon SD et al; PARAGON-HF Investigators and Committees: Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. N Engl J Med, 381:1609-1620, 2019
- 12) Setoguchi N, et al: Diuretic and renal effects of angiotensin receptor-neprilysin inhibitor in patients hospitalized for acute heart failure. Heart Vessels, 2023
- 13) Eshaghian S, et al: Relation of loop diuretic dose to mortality in advanced heart failure. Am J Cardiol, 97:1759-1764, 2006
